Scantox, a Danish provider of in-vivo preclinical research services for the pharmaceutical and medical device industries, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization.
With the acquisition of Gentronix, Scantox’s service platform expands to meet client demands as a market leading CRO to support pre-IND enabling studies.
Founded in 1999 by Prof. Richard Walmsely and led by Matt Tate, CEO, Gentronix is located within the North West UK at the Alderley Park and employs close to 70 employees after a significant scale-up over the past 5 years.
Now integrated into Scantox Group, Gentronix provides genetic toxicology solutions to the global pharma, biotech and agrichem industries; enabling clients to optimize their development programs by enabling early identification of genotoxic compounds and supporting late-stage development phases with GLP studies. The company offers a comprehensive portfolio of screening and regulatory genotoxicity assays and services, not least the OECD 488 Big Blue® Transgenic Rodent Mutation assay, as one of only three global providers. Further, Gentronix has expertise and services within ocular and skin toxicology endpoints.
Gentronix will continue to operate under the current company name, expanding its service offering within specialist regulatory toxicology. With this acquisition the Scantox Group will employ more than 400 people (led by CEO Jeanet Løgsted) across seven European sites offering first in class lead optimization, regulatory toxicology and CMC (Chemical, Manufacturing, Controls), formulation and analytical services.
FinSMEs
09/09/2024